MS
OCUL icon

Maven Securities’s Ocular Therapeutix OCUL Stock Holding History

Maven Securities’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$1.17M – 519
2025
Q3 		$1.17M Buy
+100,000
New +$1.2M 0.03% 354

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Maven Securities's OCUL Position: Q4 2025 in Review

Maven Securities sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 100,000 shares — an estimated $1.17M sold.

Maven Securities first reported a position in OCUL in Q3 2025 and held it in 1 quarter. The position peaked at $1.17M in Q3 2025. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

  • Maven Securities reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
  • Maven Securities sold 100,000 Ocular Therapeutix shares in Q4 2025, an estimated $1.17M.
  • Maven Securities first reported a position in Ocular Therapeutix in Q3 2025 and held it in 1 quarter.
  • Maven Securities's Ocular Therapeutix position peaked at $1.17M in Q3 2025.
  • 249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Maven Securities's 13F filing for Q4 2025, filed 13 Feb 2026.